FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225132364> ?p ?o ?g. }

• W4225132364 abstract "Facial seborrheic dermatitis (FSD), also called facial seborrheic eczema, is a common disease affecting both male and female patients worldwide. Tanshinone is the main bioactive component extracted from the Traditional Chinese Medicine Salvia miltiorrhiza Bunge, which is widely used in treating skin inflammatory diseases. It is necessary to evaluate the clinical evidence for tanshinone capsule treatment of FSD. This study aimed to evaluate the safety and effectiveness of tanshinone capsules combined with prednisone in the treatment of facial seborrheic dermatitis and to provide evidence for clinical practice.Studies were searched in PubMed, the Cochrane Library, the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, the Chinese Scientific Journal Database, and WanFang Database before October 2021. We also searched for randomized controlled clinical trials (RCT) of tanshinone capsules combined with prednisone on facial seborrheic dermatitis. The meta-analysis was conducted according to the guidelines of the Cochrane Handbook. Two reviewers regulated the research selection, data extraction, and risk of bias assessment, respectively, and a third reviewer was used for consulting when necessary. Review Manager Software 5.3 was used for meta-analysis.A total of 10 RCTs with 916 participants were included. Nine studies reported total effectiveness, five studies reported symptom score, seven studies reported adverse events, and four studies reported recurrence rate. The duration of treatment was 4 to 8 weeks. Combination therapy showed better clinical effects compared to the prednisone (OR: 5.82; 95% CI: 3.53, 9.59; p < 0.00001). Combination therapy could repair skin lesions (MD: -0.40; 95% CI: -0.51, -0.30; p < 0.00001), reduce skin erythema (MD: -0.58, 95% CI: -0.67, -0.49; p < 0.00001), relieve skin itch (MD: -0.70; 95% CI -0.77, -0.63; p < 0.00001), and desquamation score (MD: -0.64; 95% CI: -0.71, -0.56; p < 0.00001). Furthermore, combination therapy could reduce adverse events (OR: 0.46; 95% CI: 0.26, 0.84; p = 0.01) and control recurrence rate (OR: 0.22; 95% CI: 0.13, 0.36; p < 0.00001).Compared with prednisone, tanshinone capsules combined with prednisone may be effective in the treatment of facial seborrheic dermatitis. However, due to the high risk and ambiguity of bias in the included trials, the conclusion of this study must be interpreted carefully." @default.
• W4225132364 created "2022-05-01" @default.
• W4225132364 creator A5035783453 @default.
• W4225132364 creator A5041954647 @default.
• W4225132364 creator A5046240153 @default.
• W4225132364 creator A5065353036 @default.
• W4225132364 creator A5082178773 @default.
• W4225132364 creator A5088049626 @default.
• W4225132364 creator A5089455733 @default.
• W4225132364 date "2022-04-29" @default.
• W4225132364 modified "2023-09-26" @default.
• W4225132364 title "Tanshinone Capsules Combined With Prednisone for Facial Seborrheic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials" @default.
• W4225132364 cites W1493578925 @default.
• W4225132364 cites W1966170089 @default.
• W4225132364 cites W2098923148 @default.
• W4225132364 cites W2108696783 @default.
• W4225132364 cites W2245055311 @default.
• W4225132364 cites W2310863216 @default.
• W4225132364 cites W2548177504 @default.
• W4225132364 cites W2586708441 @default.
• W4225132364 cites W2588681363 @default.
• W4225132364 cites W2617351930 @default.
• W4225132364 cites W273205602 @default.
• W4225132364 cites W2772747033 @default.
• W4225132364 cites W2801021503 @default.
• W4225132364 cites W2883572192 @default.
• W4225132364 cites W2894040674 @default.
• W4225132364 cites W2915617311 @default.
• W4225132364 cites W2946158536 @default.
• W4225132364 cites W2966236411 @default.
• W4225132364 cites W2966975237 @default.
• W4225132364 cites W2981802129 @default.
• W4225132364 cites W2993289461 @default.
• W4225132364 cites W2999209548 @default.
• W4225132364 cites W3009944820 @default.
• W4225132364 cites W3011644616 @default.
• W4225132364 cites W3013877382 @default.
• W4225132364 cites W3029687009 @default.
• W4225132364 cites W3035989396 @default.
• W4225132364 cites W3057480612 @default.
• W4225132364 cites W3085015393 @default.
• W4225132364 cites W3096697022 @default.
• W4225132364 cites W3109932346 @default.
• W4225132364 cites W3112064602 @default.
• W4225132364 cites W3205396546 @default.
• W4225132364 cites W4236805817 @default.
• W4225132364 cites W4287467073 @default.
• W4225132364 doi "https://doi.org/10.3389/fmed.2022.816419" @default.
• W4225132364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35572959" @default.
• W4225132364 hasPublicationYear "2022" @default.
• W4225132364 type Work @default.
• W4225132364 citedByCount "1" @default.
• W4225132364 countsByYear W42251323642022 @default.
• W4225132364 crossrefType "journal-article" @default.
• W4225132364 hasAuthorship W4225132364A5035783453 @default.
• W4225132364 hasAuthorship W4225132364A5041954647 @default.
• W4225132364 hasAuthorship W4225132364A5046240153 @default.
• W4225132364 hasAuthorship W4225132364A5065353036 @default.
• W4225132364 hasAuthorship W4225132364A5082178773 @default.
• W4225132364 hasAuthorship W4225132364A5088049626 @default.
• W4225132364 hasAuthorship W4225132364A5089455733 @default.
• W4225132364 hasBestOaLocation W42251323641 @default.
• W4225132364 hasConcept C126322002 @default.
• W4225132364 hasConcept C16005928 @default.
• W4225132364 hasConcept C168563851 @default.
• W4225132364 hasConcept C17744445 @default.
• W4225132364 hasConcept C189708586 @default.
• W4225132364 hasConcept C197934379 @default.
• W4225132364 hasConcept C199539241 @default.
• W4225132364 hasConcept C2776478404 @default.
• W4225132364 hasConcept C2777484424 @default.
• W4225132364 hasConcept C2778720950 @default.
• W4225132364 hasConcept C2779473830 @default.
• W4225132364 hasConcept C71924100 @default.
• W4225132364 hasConcept C95190672 @default.
• W4225132364 hasConceptScore W4225132364C126322002 @default.
• W4225132364 hasConceptScore W4225132364C16005928 @default.
• W4225132364 hasConceptScore W4225132364C168563851 @default.
• W4225132364 hasConceptScore W4225132364C17744445 @default.
• W4225132364 hasConceptScore W4225132364C189708586 @default.
• W4225132364 hasConceptScore W4225132364C197934379 @default.
• W4225132364 hasConceptScore W4225132364C199539241 @default.
• W4225132364 hasConceptScore W4225132364C2776478404 @default.
• W4225132364 hasConceptScore W4225132364C2777484424 @default.
• W4225132364 hasConceptScore W4225132364C2778720950 @default.
• W4225132364 hasConceptScore W4225132364C2779473830 @default.
• W4225132364 hasConceptScore W4225132364C71924100 @default.
• W4225132364 hasConceptScore W4225132364C95190672 @default.
• W4225132364 hasLocation W42251323641 @default.
• W4225132364 hasLocation W42251323642 @default.
• W4225132364 hasLocation W42251323643 @default.
• W4225132364 hasOpenAccess W4225132364 @default.
• W4225132364 hasPrimaryLocation W42251323641 @default.
• W4225132364 hasRelatedWork W1967911880 @default.
• W4225132364 hasRelatedWork W2381982637 @default.
• W4225132364 hasRelatedWork W2914141471 @default.
• W4225132364 hasRelatedWork W3013041320 @default.
• W4225132364 hasRelatedWork W3027459656 @default.
• W4225132364 hasRelatedWork W3082854370 @default.
• W4225132364 hasRelatedWork W3096683796 @default.

• next